P2RY2 and cutaneous leishmaniasis: We recently reported that UTP-intralesional treatment elicited a Th1 immune response in an experimental model of cutaneous leishmaniasis [21], suggesting the involvement of P2Y2R. Here, we evaluated whether the intralesional treatment with a selective P2Y2R agonist (2-thio-UTP) would promote L. amazonensis control in BALB/c mice.